Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets. Technologies and applications include electrophoresis, imaging, multiplex immunoassay, chromatography, microbiology, protein function analysis, transfection, flow cytometry and cell sorting, amplification, and real-time and digital PCR.
Bio-Rad is an in-vitro diagnostics supplier, delivering a large portfolio of innovative products to clinical laboratories worldwide. Also the Company is a leader in clinical quality control products, services, and information systems. These products ensure the accuracy and validity of clinical test results and are used by more clinical laboratories than products from any other company. Its other diagnostic products and systems leverage a broad range of technologies and deliver high-value clinical
information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets and are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.
Company Growth (employees)
Bio-Rad Office Locations
Bio-Rad Data and Metrics
Bio-Rad Financial Metrics
Revenue (FY, 2016) | 2.1 b |
Revenue growth (FY, 2015 - FY, 2016), % | 2% |
Gross profit (FY, 2016) | 1.1 b |
Gross profit margin (FY, 2016), % | 55% |
EBIT (FY, 2016) | 53.2 m |
Market capitalization (20-Jul-2017) | 6.9 b |
Closing share price (20-Jul-2017) | 236 |
Cash (31-Dec-2016) | 456.3 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 2.1 b | 2.2 b | 2 b | 2.1 b |
Revenue growth, % | 2% | (7%) | 2% | |
Cost of goods sold | 897.8 m | 930.1 m | ||
Gross profit | 1.1 b | 1.1 b | ||
Gross profit Margin, % | 56% | 55% | ||
EBIT | 166.7 m | 53.2 m | ||
EBIT margin, % | 8% | 3% | ||
Pre tax profit | 145.8 m | 41.6 m | ||
Net Income | 77.8 m | 88.8 m | 113.1 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 331.6 m | 413.3 m | 457.5 m | 456.3 m |
Inventories | 525 m | |||
Current Assets | 1.7 b | 1.7 b | 1.8 b | 1.8 b |
PP&E | 429.4 m | 428.8 m | 437.7 m | 488.6 m |
Total Assets | 3.4 b | 3.3 b | 3.7 b | 3.9 b |
Accounts Payable | 148.5 m | 128.6 m | 122.4 m | 133.1 m |
Current Liabilities | 487.5 m | 446.8 m | 441.4 m | 471.3 m |
Total Liabilities | 1.3 b | |||
Common Stock | 2 k | 2 k | 2 k | 2 k |
Additional Paid-in Capital | 240 m | 271.3 m | 300.4 m | 332.9 m |
Retained Earnings | 1.6 b | 1.7 b | 1.8 b | 1.8 b |
Total Equity | 2.2 b | 2.2 b | 2.5 b | 2.6 b |
Financial Leverage | 1.5 x | 1.5 x | 1.5 x | 1.5 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 77.8 m | 88.8 m | 113.1 m | |
Cash From Operating Activities | 175.5 m | 273.3 m | 186.2 m | 216.4 m |
Capital Expenditures | (113 m) | (121 m) | (112 m) | (141.4 m) |
Cash From Investing Activities | (5.4 m) | (190.5 m) | (166.9 m) | (213.9 m) |
Cash From Financing Activities | (311.7 m) | 11.7 m | 8.6 m | 9 m |
Interest Paid | (61.2 m) | (20.8 m) | (20.8 m) | (21.3 m) |
Free Cash Flow | 288.5 m | 394.3 m | 298.2 m | 75 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1.5 x |
